Novartis withdraws EU applications to increase Exelon and Prometax indications
This article was originally published in Scrip
Novartis Europharm has told the European Medicines Agency (EMA) that it wishes to withdraw its applications to extend the therapeutic indications for the medicines Exelon (rivastigmine) and Prometax (rivastigmine). The company has told the agency that it will not be able to provide the additional data needed to support expansion of the indications within the timeframe allowed in the European Union's centralised procedure. .
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.